Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy

descriptionPublicationkeyboard_double_arrow_right Article 01 Aug 2018 English Publisher:Elsevier BVJournal:Cell Stem Cell, volume 23, pages 160-161 (issn: 1934-5909,

Copyright policy )

Authors: Elizabeth L, Siegler; Yanni, Zhu; Pin, Wang; Lili, Yang;

doi: 10.1016/j.stem.2018.07.007

pmid: 30075127

Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy

- Summary
- Subjects
- Metrics

Abstract

CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome. In this issue of Cell Stem Cell, Li et al. (2018) describe how engineered iPSC-derived NK cells armed with NK-tailored CAR constructs (CAR-iPSC-NK cells) provide better options for anti-cancer immunotherapy.

Related Organizations

University of California System
United States
University of California, Los Angeles
United States
University of Southern California
United States

Keywords

Killer Cells, Natural, Receptors, Chimeric Antigen, Neoplasms, Humans, Immunotherapy, Adoptive

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	135
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%